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Abstract In the present study, we have investigated the
potential of a nanoemulsion (thermodynamically stable
transparent dispersions of oil and water having a droplet
size \200 nm) formulation for the topical delivery of
COX-2 inhibitors using etoricoxib as a model drug. Vari-
ous oil-in-water nanoemulsions were prepared by the
spontaneous emulsification method. The nanoemulsion
area was identified by constructing pseudo-ternary phase
diagrams. The prepared nanoemulsions were subjected to
thermodynamic stability testing. Those that passed these
tests were characterized for viscosity, droplet size and
differential scanning calorimetry. Topical permeation of
etoricoxib through porcine abdominal skin was estimated
using the Franz diffusion cell. The ex vivo skin permeation
profile of optimized formulations was compared with that
of etoricoxib conventional gel. A significant increase in
permeability was observed in optimized nanoemulsion
formulations consisting of 2 % w/w of etoricoxib, 20 %
w/w of Triacetin, 38 % w/w of a surfactant mixture
(Cremophor RH 40:Transcutol P), and 42 % w/w of water.
The anti-inflammatory effects of this formulation on car-
rageenan-induced paw edema in rats showed a significant
increase in the percent inhibition value (84.61 % with the
nanoemulsion gel and 92.30 % with the nanoemulsion) as
compared with the conventional gel (69.23 %) after 6 h
when compared with etoricoxib conventional gel. These
results suggest that nanoemulsions can serve as potential
vehicles for improved transdermal delivery of anti-
inflammatory agents such as etoricoxib.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the
most commonly used drugs to reduce pain and inflamma-
tion (Escribano et al. 2003; Lee et al. 2003). COX-2
inhibitors that have been introduced in medical practice are
recommended orally for patients with chronic inflamma-
tory degenerative diseases such as rheumatoid arthritis and
osteoarthritis (Li et al. 2005), and also as anti-inflamma-
tory, antipyretic, and analgesic agents (Yang et al. 2002).
The chronic oral administration of these causes gastroin-
testinal ulcers, bleeding and adverse cardiovascular events
(Lehmann et al. 2001; Yamazaki et al. 1997). Use of the
transdermal route eliminates these side effects, increases
patient compliance, avoids first-pass metabolism, and
maintains the plasma drug levels (Gaurel et al. 1997).
Therefore, an improved nanoemulsion formulation of
COX-2 inhibitors such as etoricoxib with a high degree of
permeation could be useful in the treatment of locally
inflamed skin and inflammatory and painful states of sup-
porting structures of the body, such as bones, ligaments,
joints, tendons, and muscles (Alvarez-Figueroa and
Blanco-Mendez 2001). There has been an increased inter-
est during recent years in the use of topical vehicle systems
that could modify drug permeation through the skin. Many
of the dermal vehicles contain chemical enhancers and
solvents to achieve these goals (Peltola et al. 2003; Walters
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et al. 1989). But use of these chemical enhancers may be
harmful, especially on chronic application, as many of them
are irritants. Therefore, it is desirable to develop a topical
vehicle system that does not require the use of chemical
enhancers to facilitate drug permeation through the skin.
One of the most promising techniques for enhancement of
transdermal permeation of drugs are nanoemulsions and
nanoemulsion gels. These are thermodynamically stable
transparent (translucent) dispersions of oil and water sta-
bilized by an interfacial film of surfactant and cosurfactant
molecules having a droplet size of less than 200 nm (Shafiq
et al. 2000; Shafiq et al. 2007; Rhee et al. 2001). Due to their
characteristic size and properties, which include kinetic
stability, they are very effective in enveloping and/or sol-
ubilizing drugs and successfully transferring them toward
suitable targets. Many studies have shown that nanoemul-
sion formulations possess improved transdermal and dermal
delivery properties for drugs in vitro, as well as in vivo over
conventional topical formulations such as emulsions and
gels (Gonzalez et al. 1994; Kemken et al. 1992; Osborne
et al. 1991). This article describes the potential use of
nanoemulsion-based gel systems for the transdermal
delivery of etoricoxib using nonirritating, pharmaceutically
acceptable ingredients without using additional permeation
enhancers, since the excipients themselves act as perme-
ation enhancers (Kreilgaard et al. 2000; Kriwet and Muller-
Goymann 1995; Trotta 1999).
Experiment
Materials and methods
Etoricoxib (EXB) was received as a gift sample from
Genovo Development Services, Bangalore. Polyoxyethyl-
ene 80 sorbitan monooleate, sorbitan oleates, soyabean
lecithin, polyoxyl 40 hydrogenated castor oil, diethylene
glycol monoethyl ether, sodium lauryl sulfate, propylene
glycol, polyethylene glycol (400, 600), Carbopol-934,
Poloxamer 407 were obtained from Sigma Laboratories,
Mumbai (India). Isopropyl myristate (IPM), oleic acid,
glycerol triacetate (Triacetin), olive oil, were obtained from
E-Merck (Mumbai, India). Polyoxy-35-castor oil (Cremo-
phor RH 40) and diethylene glycol monoethyl ether
(Transcutol P) were gift samples from Gattefosse, Cedex,
France. All other chemicals used in the study were of
analytical reagent grade.
Screening of excipients
Compatibility studies were carried out to investigate
interactions between the drug and the polymers. Interaction
studies were carried out by infrared spectroscopy and DSC.
The solubility of EXB in various oils (Triacetin, castor
oil, oleic acid, IPM, and olive oil), surfactants (Polyoxy-
ethylene 80 sorbitan monooleate, sorbitan oleates, polyoxyl
40 hydrogenated castor oil, diethylene glycol monoethyl
ether, propylene glycol) was determined by dissolving an
excess amount of EXB in 5 ml of each of the selected oils,
surfactants and cosurfactants. The vials were then kept at
37 ± 1.0 C for 72 h to equilibrate and centrifuged at
3,000 rpm for 15 min. The supernatant was filtered through
a 0.45-lm membrane filter. The concentration of EXB was
determined by a validated HPLC method using a UV
detector at 284 nm.
Preparation of nanoemulsions
Various formulations of nanoemulsions (using different
concentrations of excipients) of EXB were prepared by the
low energy emulsification method (aqueous titration
method). Optimized formulations of nanoemulsions were
prepared by dissolving 2 % w/w of EXB in a 10–20 % w/w
mixture of the oily phase. Then, 30–45 % w/w mixture of
Smix (surfactant:cosurfactant) was added slowly to the oil
phase, followed by the slow addition of distilled water to
adjust the final preparation to 100 % w/w. The composi-
tion of the various batches prepared is given in Table 1.
Construction of pseudo-ternary phase diagrams
On the basis of solubility studies, Triacetin was selected as
the oil phase with high solubility of the drug
(96.84 ± 1.89 mg/ml). Cremophor RH 40 (HLB-14) and
Transcutol P (HLB-4.2) were selected as surfactant and
cosurfactant, respectively, since a stable, transparent
nanoemulsion was obtained with them. Surfactant and
cosurfactant (Smix) were mixed in various weight ratios
Table 1 Composition of various batches of nanoemulsion
formulations
Batch no. Smix ratio Oil phase (%) Smix (%) Aqueous
phase (%)
F1 1:0 10 67 23
F2 1:0 15 60 25
F4 3:1 15 50 35
F5 3:1 10 36 54
F6 3:1 20 50 30
F7 2:1 10 35 55
F8 2:1 15 39 46
F9 2:1 20 38 42
F10 1:1 10 50 40
F11 1:1 15 35 50
F13 4:1 20 22 58
F14 4:1 15 26 59
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(1:0, 1:2, 1:3, 1:1, 2:1, 3:1 and 4:1). These Smix ratios were
selected in increasing concentrations of surfactant with
respect to the cosurfactant and increasing concentration of
cosurfactant with respect to surfactant for a detailed study
of the phase diagrams as required for nanoemulsion for-
mation. The physical state of the nanoemulsion was
marked on a pseudo-3-component phase diagram with one
axis representing the aqueous phase, second representing
oil, and the third representing a mixture of surfactant and
cosurfactant in fixed weight ratios (Fig. 1). Various com-
binations of oil and Smix (from 1:9 to 9:1) (Table 2) were
prepared so that maximum ratios were covered for the
study to delineate the boundaries of phases precisely
formed in the phase diagrams. Pseudo-ternary phase dia-
grams of oil, Smix, and aqueous phase were developed
using the aqueous titration method (Barzin and Sadatnia
2007). The aqueous phase was slowly titrated with the
weight ratio of oil and Smix, and visual observations were
made for transparent and easily flowable oil-in-water (o/w)
nanoemulsions (Craig et al. 1995; Lawrence and Rees
2000).
Selection of nanoemulsion formulations
From each phase diagram constructed, different combina-
tions were selected from the nanoemulsion region so that
the drug etoricoxib (2 % w/w) could be incorporated into
the oil phase. Selected formulations were subjected to
thermodynamic stability testing (Li et al. 2005).











Fig. 1 Phase diagrams constructed for preparation of nanoemulsions
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Preparation of etoricoxib gel
EXB gel was prepared by dispersing the gelling agent
Carbopol-934 (0.5–1.5 %) in the required quantity of dis-
tilled water and kept in the dark for 24 h for complete
swelling. Then, 2 % w/w of EXB in a specific quantity of
the nanoemulsion solution was added slowly into this
aqueous dispersion. Finally, triethanolamine (TEA) was
added to obtain a homogeneous dispersion of the gel.
Thermodynamic stability studies
To overcome the problem of metastable formulations,
thermodynamic stability tests were performed. The selec-
ted formulations were centrifuged at 3,500 rpm for 15 min.
The formulations that did not show any phase separation
were subjected to the heating and cooling cycle. Six cycles
between refrigeration temperature (4 C) and 45 C with
storage at each temperature of not less than 48 h were
done. The formulations, which were stable at these tem-
peratures, were further subjected to a freeze–thaw cycle
between -4 and 25 C. The formulations that survived
these thermodynamic stability tests were considered for
further studies (Shinoda and Kunieda 1983; Delgado-
Charro et al. 1997).
Droplet size analysis
Droplet size distribution of the nanoemulsion was deter-
mined by photon correlation spectroscopy that analyzes
fluctuations in light scattering due to Brownian motion of
the particles, using a Zetasizer 1000 HS (Malvern Instru-
ments, UK). The formulation (0.1 ml) was dispersed in
50 ml of water, mixed thoroughly and light scattering was
carried out at an angle of 90 at 25 C.
Rheological studies and viscosity measurements
The viscosity of the formulations was determined using a
Brookfield Cup and Bob Viscometer (Brookfield Engi-
neering Laboratories, Middleboro, MA) at 25 ± 0.3 C
and 100 rpm (Lawrence and Rees 2000).
Permeation studies
In vitro skin permeation studies were performed using
porcine abdominal skin with a Franz diffusion cell having
an effective diffusion area of 0.785 cm2 and 4 ml receiver
chamber capacity. Full-thickness porcine skin was excised
from the abdominal region and hair was removed with an
electric clipper. The subcutaneous tissue was removed
surgically, and the dermis side was wiped with isopropyl
alcohol to remove adhering fat. The leaned skin was
washed with distilled water and stored in the deep freezer
at 0 C until further use. The skin was brought to room
temperature and mounted between the donor and receiver
compartments of the Franz diffusion cell, with the stratum
corneum side facing the donor compartment and the dermal
side facing the receiver compartment. The thickness of the
skin was 50–70 lm as measured with a validated
micrometer screw gauge.
The receiver chamber was filled with phosphate-buf-
fered saline (PBS) solution pH 7.4, stirred with a magnetic
rotor at a speed of 50 rpm, and maintained at a temperature
of 37 ± 1 C. A quantity of the nanoemulsion diluted with
50 % water was used for the release studies. Since the
nanoemulsion had 2 % (20 mg/ml) of the drug, the final
drug concentration in the gel was 10 mg/ml which was
equivalent to the amount in the marketed formulation.
One ml of the optimized nanoemulsion formulation
(equivalent to 10 mg/ml ETX) or 1 g of a conventional gel
(10 mg/g) was placed in the donor compartment and sealed
with paraffin film to provide occlusive conditions. Samples
were withdrawn at regular intervals (0.5, 1, 2, 3, 4, 5 and
6 h) and sink conditions were maintained by replacement
with fresh medium. Samples were filtered through a 0.45-
lm membrane filter and analyzed for drug content by a
validated HPLC method using a UV detector at 284 nm.
The HPLC system used was Jasco PU 1580 with Chrom-
pass software. HPLC conditions included: column HiQ Sil
C8, flow rate 1 ml/min, mobile phase methanol:acetoni-
trile:water (55:23:32), retention time 4.2 min. Each
experiment was conducted in triplicate (Dreher et al. 1997;
Gasco et al. 1991; Krielgaard 2001; Krielgaard et al. 2001;
Ktistis and Niopas 1998).
Histopathological examination of skin specimens
The skin specimens subsequent to in vitro permeation
studies were histopathologically examined. They were
stored in 10 % formalin solution. Vertical sections were
dehydrated using ethanol, embedded in paraffin for fixing
and stained with hematoxylin and eosin. These samples
were then observed under a light microscope (Motic,
Tokyo, Japan) and compared with the control sample.
Three different sites of each were scanned and evaluated
for possible abnormalities due to the formulation.
In vivo efficacy studies
In vivo studies were carried out as per a protocol approved
by the CPCSEA and Institutional Animal Ethics Commit-
tee (IAEC). The anti-inflammatory and sustaining action of
the optimized formulation was evaluated in Wistar rats by
the carrageenan-induced hind paw edema method devel-
oped by Winter (1965). Formulation F9 was selected for
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the study of in vivo anti-inflammatory effects based on its
higher drug permeation, lowest droplet size and lowest
viscosity for better dispersion properties. Thirty rats
weighing between 120 and 150 g were randomly catego-
rized into five groups each containing six rats: normal,
toxicant, Test 1 [nanoemulsion (F9)], Test 2 [nanoemul-
sion gel (NG)], and conventional gel (CG). The animals
were kept under standard laboratory conditions, at
25 ± 1 C and relative humidity 55 ± 5 %. The animals
were housed in polypropylene cages, six per cage, with
free access to a standard laboratory diet and water
ad libitum. The dose for the rats was calculated based on
the weight of the rats according to the surface area ratio
(Gosh 2005). Paw edema was induced by injecting 0.1 ml
of a 1 % w/w homogeneous suspension of carrageenan in
distilled water. Control, F9, NG, and CG were applied on
the hind paw region of all animals (except in normal
group) half an hour before sub-planter injection of car-
rageenan in the right paws. The volume of paw was
measured at 1, 2, 3, 4, 5, 6, and 24 h after injection using
a digital plethysmometer and expressed as percent edema
relative to initial hind paw volume. Percent inhibition of
edema produced by each formulation-treated group was
calculated against the respective control group. Results of
anti-inflammatory activity were compared using the
Dunnett’s test of one-way ANOVA.
Results and discussion
The excipients interaction studies were carried out by
infrared spectroscopy (Table 3) and DSC (Figs. 2, 3). The
excipients selected for the formulation are pharmaceuti-
cally acceptable, nonirritating, and non-sensitizing to the
skin and belong to the generally regarded as safe (GRAS)
category. Higher solubility of the drug in the oil phase was
another important criterion, as it would help the nano-
emulsion maintain the drug in a solubilized form.
As is evident from Figs. 2 and 3, there is no interaction
between the drug and selected excipients.
The surfactants were selected based on formation of the
most stable mixture. This was evaluated on the basis of
appearance, viscosity and droplet size. Only combinations
1:0, 1:1, 2:1, 3:1 (Fig. 1) produced formulations that
formed effective nanoemulsions and were stable; the other
ratios gave an unstable formulation and/or a narrow range
of nanoemulsion formation.
Nanoemulsion droplet size analysis
The droplet size increased with the increase in concentra-
tion of oil in the formulations. All the formulations had
droplets in the nano-range. Polydispersity is the ratio of
standard deviation to mean droplet size and indicates the
Table 3 Comparison of IR
spectra of pure drug and
formulation




1 C–H 2,962–2,853 stretch 2,852.82 2,853.16
2 C–C 1,600–1,450 stretch 1,598.99 1,593.74
3 C–H 1,470–1,430 bend 1,427.32 1,430.29
4 C–N 1,360–1,310 vibration 1,309.67 1,311.78
5 S=O 1,160–1,140 1,153.43 1,154.21
6 C–Cl 800–600 721.7 722
Fig. 2 DSC thermogram of
etoricoxib
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uniformity of droplet size within the formulation: higher
the polydispersity, lower the uniformity of the droplet size
in the formulation. Although the polydispersity values of
all the formulations was very low, indicating uniformity of
droplet size within each formulation, the polydispersity
of formulation F9 was lowest (0.452). Also, the droplet size
of formulation F9, containing 10 % oil, was lowest (50 nm)
(Table 4). The droplet size distribution of the optimized
nanoemulsion formulation (F9) is shown in Fig. 4.
Rheological studies
Most nanoemulsions possess a very low viscosity and,
therefore, their application may be inconvenient. In order
to overcome this disadvantage, a gelling agent such as
Carbopol-934 was used to increase the viscosity of the
nanoemulsion forming a nanoemulsion-based gel which is
more suitable for topical application. A suitable viscosity
of Carbopol-934 also results in enhanced skin permeation
of the drug due to constant contact of the preparation with
skin. The observed viscosities of all the formulations pre-
pared were in range 3,000–3,500 cps making the formu-
lated product suitable for topical administration. For some
fluids, viscosity is a constant over a wide range of shear
rates (Newtonian fluids). The fluids without a constant
viscosity (non-Newtonian fluids) cannot be described by a
single number. Non-Newtonian fluids exhibit a variety of
different correlations between shear stress and shear rate.
The system prepared was non-Newtonian shear thinning
since the viscosity decreases with rate of shear stress.
Permeation studies
The ex vivo permeation profiles of ETX through excised
dorsal porcine skin are shown in the graph (Fig. 5). A
steady increase in the concentration of ETX in the receptor
chamber with time is observed. Statistical evaluation of the
Fig. 3 DSC thermogram of
formulation






F1 89.33 ± 4.04 0.67 ± 0.17 90.44 ± 5.44
F4 83.33 ± 4.73 0.81 ± 0.16 81.10 ± 3.23
F9 50.67 ± 6.03 0.44 ± 0.08 80.06 ± 4.19
NG 86.67 ± 5.51 2.24 ± 0.11 3,256.69 ± 43.41
Fig. 4 Droplet size distribution
of optimized nanoemulsion
formulation (F9)
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flux throughout the 6 h of study showed that among all the
formulations, nanoemulsions F4 and F9 exhibited maxi-
mum permeation (above 90 %) at the end of 6 h, while the
cumulative permeation of ETX from the nanoemulsion-
based gel (NG) and conventional gel (CG) containing the
same amount of ETX were 80 and 70 %, respectively, 6 h
post-application. Higher release was obtained with the fluid
nanoemulsions than the viscous gels due to increased
penetration through the membrane.
Histopathological studies
The photomicrographs of untreated porcine skin (control)
showed normal skin with well-defined epidermal and der-
mal layers (Fig. 6).
Skin appendages were within normal limits (Fig. 6A,
B), and skin was treated with nanoemulsion formulation
(F9, NG) for 24 h (Fig. 6C, D).
These observations support the compatibility of the
formulation with skin. There were no apparent signs of skin
irritation (erythema and edema) observed on visual exam-
ination of the skin specimens treated with nanoemulsion
formulations indicating absence of any skin irritation as a
consequence of nanoemulsion treatment.
Fig. 5 Ex vivo permeation studies on nanoemulsion (NE) (F4, F9),
nanoemulsion gel (NG) and conventional gel (CG)
Fig. 6 Photomicrograph of histopathological analysis of porcine abdominal skin
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In vivo efficacy studies
The percent inhibition values 6 h post-administration were
found to be high for nanoemulsion formulations (F4, F9) as
compared with conventional gel (CG); this difference was
significant (P \ 0.05). The percent inhibition values for the
formulations are shown in Table 5.
Skin irritation test
No erythema was observed on visual inspection after
application of ETX nanoemulsion formulations on rat skin.
Thus, the developed formulation is non-sensitizing and safe
for use.
Conclusion
In this work, a nanoemulsion-based gel formulation with
suitable viscosity for topical administration has been
developed to deliver anti-inflammatory agents such as
etoricoxib. The optimized formulation contained 20 % of
oil phase (Triacetin), 38 % of surfactant mixture (Cremo-
phor RH 40 and Transcutol P) and 42 % of distilled water.
From the studies, it is observed that the formulated nano-
emulsions and nanoemulsion gel released up to 90 and
80 % of the drug, respectively, as compared to 70 % from
the conventional gel product. The formulation was non-
sensitizing and safe for use prepared with nonirritating,
pharmaceutically acceptable ingredients. No additional
permeation enhancers were needed to be added since the
excipients themselves acted as permeation enhancers. A
high percent inhibition of edema was observed with the
nanoemulsion (92.30 %) and nanoemulsion gel (84.61 %)
as compared with the conventional gel (69.23 %). Thus, it
can be concluded that the developed nanoemulsion-based
gels have a greater potential for topical drug delivery as
compared to conventional formulations.
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